title: Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes.
abstract: Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark. Electronic address: mmp@ki.au.dk.
authors.forename: Morten Møller
authors.initials: MM
authors.lastname: Poulsen
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark.
authors.forename: Karen
authors.initials: K
authors.lastname: Fjeldborg
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark.
authors.forename: Marie Juul
authors.initials: MJ
authors.lastname: Ornstrup
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark.
authors.forename: Thomas Nordstrøm
authors.initials: TN
authors.lastname: Kjær
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark.
authors.forename: Mark Klitgaard
authors.initials: MK
authors.lastname: Nøhr
authors.affiliation: Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark.
authors.forename: Steen Bønløkke
authors.initials: SB
authors.lastname: Pedersen
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D057170:Translational Research, Biomedical
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D000077185:Resveratrol
keywords: Clinical trial; In vitro; In vivo; Inflammation; Metabolism; Resveratrol